Get the Stockscreener App
84.47
0.51%
-0.43
After Hours:
84.50
0.03
+0.04%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $84.47, with a volume of 12.91M.
It is down -0.51% in the last 24 hours and down -16.83% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$84.90
Open:
$85.89
24h Volume:
12.91M
Relative Volume:
1.09
Market Cap:
$147.13B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
23.53
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+0.18%
1M Performance:
-16.83%
6M Performance:
-35.32%
1Y Performance:
-36.66%
1-Day Range:
$84.13
$86.47
1-Week Range:
$81.97
$86.47
52-Week Range:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
84.47 | 147.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
306.76 | 117.12B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.15 | 98.82B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
52.68 | 79.59B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.38 | 46.84B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories stock (US0028241000): diabetes segment drives attention after latest quarterly u - AD HOC NEWS
Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment - simplywall.st
ABT (NYSE: ABT) Form 144 shows 7,587 RSU shares and prior 29,211 sale - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
Is the options market predicting a spike in Abbott Laboratories stock? - MSN
Abbott Laboratories stock (US0028241000): Q1 beat, Exact Sciences deal and legal risks keep investor - AD HOC NEWS
Abbott class action alleges FreeStyle Libre 2 glucose monitor is defective - Class Action Lawsuits
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up - Yahoo Finance
Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT) - simplywall.st
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
ABT Stock Quote Price and Forecast - CNN
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B - AD HOC NEWS
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment - Insider Monkey
Abbott Laboratories stock (US0028241000): shares rebound after earnings and guidance update - AD HOC NEWS
Insider trades: Okta and Abbott see buys, Micron insiders sell - MSN
What to know about Kyle Diamantas, the new acting FDA commissioner - The Guardian
How The Investment Narrative For Abbott Laboratories (ABT) Is Shifting With Recent Analyst Resets - Yahoo Finance
Nvision secures $55 million, with backing from Abbott - BioWorld News
Abbott Eterna Lawsuit Alleges Spinal Cord Stimulator Malfunction Resulted in Worsening Pain - AboutLawsuits.com
Abbott Laboratories Deadline Alert - TMX Newsfile
Abbott Laboratories stock (US0028241000): Q4 earnings call set for Jan. 22 - AD HOC NEWS
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold? - Yahoo Finance
Abbott Securities Lawsuit Deepens Infant Formula Risks For Shareholders - simplywall.st
Abbott India Limited Issues Postal Ballot Notice for Appointment of Mr. James Wenner and Mr. Neeraj Jain to Its Board - scanx.trade
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Q1 2026 earnings beat sends Abbott stock higher by 3.04% - Traders Union
Abbott’s dividend yield near decade peak as investors weigh litigation costs By Investing.com - Investing.com Nigeria
Abbott’s dividend yield near decade peak, signaling rare buying opportunity - Investing.com
Abbott Laboratories stock (US0028241000): Q1 earnings beat with $11.16B revenue - AD HOC NEWS
ABT Stock Price, Quote & Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
Could Cash Machine Abbott Laboratories Stock Be Your Next Buy? - Trefis
Operating margin % of Abbott Laboratories Shs UnSponsored Canadian Depository Receipt Hedged – TSX:ABT - TradingView
Jim Cramer says today’s market is punishing stocks harder than 1999 - CNBC
Abbott Laboratories Shs UnSponsored Canadian Depository Receipt Hedged Statistics – TSX:ABT - TradingView
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Why is Abbott Laboratories stock down today? - Traders Union
Abbott Stock Down 38% in 2026: Does the $23 Billion Exact Sciences Acquisition Change the Math? - TIKR.com
Abbott Laboratories trades at decade low with growth and dividend streak, poised for EPS boost by 2028-29. - Pluang
Abbott: Three Supercycles, Mispriced At A 10-Year Low - Seeking Alpha
Abbott Laboratories stock (US0028241000): Q1 earnings beat estimates with $11.16B revenue - AD HOC NEWS
Abbott Laboratories stock (US0028241000): Kepler Cheuvreux Suisse buys new stake - AD HOC NEWS
Wearable Skin Patch Market Size Propelled by 12.8% CAGR | - openPR.com
Implantable Medical Devices Market Is Going to Boom | Medtronic, Abbott Laboratories - openPR.com
Helicobacter Pylori Testing Market Is Going to Boom | Abbott Laboratories, Roche Diagnostics, Siemens Healthineers - openPR.com
Lateral Flow Assay Component Market Is Going to Boom | Abbott Laboratories, BD - openPR.com
Abbott Laboratories (ABT) Stock Analysis: Strong Buy Ratings Signal Potential 40.7% Upside - DirectorsTalk Interviews
A Look At Abbott Laboratories (ABT) Valuation After Mixed Q1 Results And Baby Formula Legal Ruling - Yahoo Finance
Is It Time To Reconsider Abbott Laboratories (ABT) After The Recent Share Price Slump? - simplywall.st
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbott Laboratories Stock (ABT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
0.41%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):